NCT07897279|Completed
Evaluation of Assisted Reproductive Technology (ART) Outcomes in Couples With Nonobstructive Azoospermia, Cryptozoospermia, and Severe Oligozoospermia
ART
Loading search results
ART
Sponsor study identifier
observational
80
1 country
1
Study Start
November 1, 2019
Actual (reported)Primary Completion
September 30, 2023
Actual (reported)Study Completion
December 30, 2023
Actual (reported)This study aims to compare the In Vitro Fertilization (IVF/ICSI) outcomes of patients with a sperm concentration of \<5 million/mL (severe oligozoospermia) and \<1 million/mL (cryptozoospermia) to those diagnosed with nonobstructive azoospermia (NOA). Men are categorized into three groups: NOA, cryptozoospermia (CRYP), and severe oligozoospermia (SO). These three groups are compared in terms of beta-hCG positivity, clinical pregnancy rate, live birth rate, and early pregnancy loss.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 30, 2023
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 1, 2019
Actual (reported)September 30, 2023
Actual (reported)December 30, 2023
Actual (reported)October 15, 2026
Actual (reported)October 27, 2026
Actual (reported)beta-hCG positivity
\<20 serum beta-hCG level
4 years
ongoing pregnancy
Detection of fetal cardiac activity on ultrasound
4 years
live birth rate
live birth \> 24 weeks of gestation
4 years
cryptozoospermia (CRYP)
Data from 1,430 patient files who applied to the Assisted Reproductive Treatment Center of Ankara Bilkent City Hospital between November 2019 and September 2023, were evaluated retrospectively. Among these, data from 80 men with no detected major or minor chromosomal anomalies, including Y-chromosome microdeletions, who were admitted to the assisted reproductive technology (ART) program solely due to male infertility, were analyzed. Patients were divided into three groups based on their spermiogram results: Non-obstructive azoospermia (NOA Group), sperm concentration ≤1 million/mL (CRYP Group), and sperm concentration 1-5 million/mL (SO Group). Data for the study cohort were obtained via a retrospective review of hospital and clinic registries.
Assisted Reproductive Treatment Center of Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
Datta AK, Campbell S, Diaz-Fernandez R, Nargund G. Livebirth rates are influenced by an interaction between male and female partners' age: analysis of 59 951 fresh IVF/ICSI cycles with and without male infertility. Hum Reprod. 2024 Nov 1;39(11):2491-2500. doi: 10.1093/humrep/deae198.
Merve Tepecik
Çankırı State Hospital
Zehra Kurdoğlu
Ankara City Hospital Bilkent
80 participants (actual enrollment reported by the registry).
First Submitted
October 15, 2026
First Posted
October 27, 2026
Study Start
November 1, 2019
Actual (reported)DNA Amplification in Blastocoel Fluid
Contact the study team to confirm eligibility.
Primary Completion
September 30, 2023
Actual (reported)Study Completion
December 30, 2023
Actual (reported)Last Updated
October 27, 2026
Record last verified: 2026-10
Demographic data of women and controlled ovarian stimulation parameters-including age, body mass index (BMI), gravidity, parity, systemic diseases, smoking status, duration of infertility, number of previous IVF failures, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P), serum AMH level, antral follicle count (AFC), total gonadotropin dose, and duration of ovulation induction- Trigger day parameters (peak estradiol and progesterone levels, endometrial thickness, and number of follicles \> 14 mm) and embryological data (numbers of retrieved, mature \[MII\], and fertilized oocytes, total embryo yield, and the specific day, grade, and number of transferred embryos) . Clinical ART outcomes as beta-hCG positivity, clinical pregnancy rates (CPR), early pregnancy losses, and live birth rates (LBR).
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: